CD19/CD70 CAR-NK cells therapy (Rongu Biotechnology)

N/A

Report date: 2024/07/31 15:38:09

Base Information

Drug NameCD19/CD70 CAR-NK cells therapy (Rongu Biotechnology)
Drug Alias NameRG-1970
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-CD19Anti-CD70Natural killer cell replacements
TargetsB-lymphocyte antigen CD19CD70 antigen
Therapy Area/IndicationsLymphoma, B-CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHangzhou Rongu Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Rongu Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A